Literature DB >> 32426922

Application of metabolomics to the study of irritable bowel syndrome.

Sean M Bennet1, Ammar H Keshteli2, Premysl Bercik3, Karen L Madsen2, David Reed1, Stephen J Vanner1.   

Abstract

The pathophysiology of irritable bowel syndrome and the detection of biomarkers of specific mechanisms and/or predictors of therapeutic response remain elusive. This roadblock reflects, in large part, the complexity and heterogeneity of the disorder. Recently, there has been growing evidence of a dietary and/or microbiome interaction with the host that may trigger symptoms in a subset of patients. While a number of techniques are available to examine these potential interactions, "omic" approaches such as metabolomics are becoming more widely used. Metabolomics measures hundreds and potentially thousands of known and unknown small molecule chemicals (metabolites) to provide a unique look into mechanisms that underlie symptom generation and potential predictors of therapeutic response. In this issue of the journal, Lee et al use nuclear magnetic resonance (NMR) to demonstrate the value of this approach to study IBS. This review examines the use of metabolomics to better understand IBS, focusing on what has been learned to date, practical and technical considerations, its potential for future research and how the study by Lee et al have contributed to these concepts.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  irritable bowel syndrome; mass spectometry; metabolites; metabolomics; microbiota; nuclear magnetic resonance

Mesh:

Year:  2020        PMID: 32426922     DOI: 10.1111/nmo.13884

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  4 in total

Review 1.  The Influence of Nutrition on Intestinal Permeability and the Microbiome in Health and Disease.

Authors:  Orsolya Inczefi; Péter Bacsur; Tamás Resál; Csilla Keresztes; Tamás Molnár
Journal:  Front Nutr       Date:  2022-04-25

2.  Baseline Predictors of Discontinuation of Prescription Drug Therapy for IBS-C: Cohort Analysis at an Integrated Healthcare System.

Authors:  Eric D Shah; Darren M Brenner; Vincent L Chen
Journal:  Dig Dis Sci       Date:  2021-03-29       Impact factor: 3.199

3.  Functional Gastrointestinal Disorders and the Microbiome-What Is the Best Strategy for Moving Microbiome-based Therapies for Functional Gastrointestinal Disorders into the Clinic?

Authors:  Ruben A T Mars; Mary Frith; Purna C Kashyap
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 22.682

Review 4.  Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome.

Authors:  Yoshiyuki Mishima; Shunji Ishihara
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.